From Spyre Therapeutics Prices Public Offering of Shares

How does the Spyre Therapeutics equity offering affect Stifel?

Stifel serves as joint book-running manager for Spyre Therapeutics offering Stifel is participating in the underwritten public offering of Spyre Therapeutics common stock. The company is selling 4,117,648 shares at a price of $85.00 per share. Stifel shares the management duties as a joint book-running manager alongside Jefferies, TD Cowen, and Leerink Partners.

Reported by 1 independent outlet Written Oct 6

Effect: Mild positive
How direct: Stated in the reporting
When: Right away
The story: Gone quiet

How it reaches Stifel

Reported by news outlets

The offering involves Spyre Therapeutics, which is seeking gross proceeds of approximately $350.0 million. This funding is intended to advance the company's programs in Gastroenterology, Rheumatology, and Dermatology, including funding preclinical studies, clinical trials, manufacturing, and Phase 3 readiness.

1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- manilatimes.net Oct 1

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

The offering is for Spyre Therapeutics, Inc., a clinical-stage biotechnology company.manilatimes.net
The offering price is set at $85.00 per share.manilatimes.net
The gross proceeds expected from the offering are approximately $350.0 million.manilatimes.net
Stifel is one of the joint book-running managers alongside Jefferies, TD Cowen, and Leerink Partners.manilatimes.net

Why it matters

As a joint book-running manager, Stifel is centrally involved in the capital raise for Spyre Therapeutics. This role places Stifel at the forefront of the company's financing efforts, which are critical for its pipeline development.

The funds raised are earmarked for various operational needs, including advancing programs in Gastroenterology, Rheumatology, and Dermatology. This successful offering could provide a significant financial boost to the company's operational capacity and future research goals.

What we don't know yet

What are the specific terms of the management agreement between the joint book-running managers?
How will the proceeds be allocated among the various research and development programs?

What would change this answer

The offering closes successfully with the expected proceeds.The successful close validates the offering structure and secures the necessary capital for Spyre Therapeutics' continued operations.

Any major unforeseen market shifts occur.The successful execution of the offering could be complicated by market volatility or changes in the regulatory landscape.

— Other considerations

Beyond this explainer

Explore connected ideas

Each opens a map of what the web connects to it, with Brind's news on it.

Stifel Underwritten Public Offering Clinical Trials Biotechnology Company Research and Development Gross Proceeds Regulatory Landscape Market Volatility

The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.

Reporting

manilatimes.netOct 1

Keep going

The full eventSpyre Therapeutics Prices Public Offering of Shares Everything aboutStifel

Brind's analysis is written by AI from the reporting linked above and can be wrong. It is not investment advice; do your own research.